Daewoong wins permission for Nabota in Argentina

The S.Korean drugmaker plans to release its botulinum toxin product through the distribution channels of the local firm

Daewoong wins permission for Nabota in Argentina
Young-ae Lee 1
2024-07-15 15:35:32 0ae@hankyung.com
Bio & Pharma

South Korea's Daewoong Pharmaceutical Co. announced on Monday that its botulinum toxin Nabota received product approval from Argentina's National Administration of Drugs, Food and Medical Technology (ANMAT) last month.

The Argentine name is Clodew.

Daewoong plans to launch Clodew in Argentina through its local partner Oxapharma in the fourth quarter of this year and will actively engage in brand marketing.

Daewoong explained that this is the first time a domestically produced botox has received product approval in Argentina.

According to Daewoong Pharmaceutical, Argentina is an attractive market, ranking fourth for the average number of botox procedures per capita last year.

However, the company said that entering the market is challenging due to high entry barriers, such as the requirement for Good Manufacturing Practice (GMP) certification from high-surveillance countries recognized by the Argentine government, including the US and Europe.

Write to Young-ae Lee at 0ae@hankyung.com
#Daewoong Pharmaceutical #Nabota #botulinum toxin #Clodew #ANMAT #Oxapharma

Daewoong, Indonesia's IPB to co-research on primate

Daewoong, Indonesia's IPB to co-research on primate

South Korea's Daewoong Pharmaceutical Co. announced on Thursday that it signed a contract with Indonesia's Bogor Agricultural University (Institut Pertanian Bogor, IPB) for joint research on primates.Daewoong Pharmaceutical will collaborate with IPB to establish a specialized primate research

Daewoong Pharmaceutical digitizes DB of 800 mn chemical compounds

Daewoong Pharmaceutical digitizes DB of 800 mn chemical compounds

South Korea's Daewoong Pharmaceutical announced on Monday that it has established a drug development system Daewoong AI System (DAISY) which combines an 800 million-compound molecular model database with an artificial intelligence (AI) target substance discovery system.According to the company

Daewoong gets stem cell facility license in Indonesia

Daewoong gets stem cell facility license in Indonesia

South Korea's Daewoong Pharmaceutical announced on Tuesday that its subsidiary Daewoong Biologics Indonesia has obtained a stem cell Lab Operational License from the Indonesian Ministry of Health.The stem cell processing facility license permits facilities to research and produce stem cells. T

Daewoong exports $92.4 mn Depot injection tech to UAE

Daewoong exports $92.4 mn Depot injection tech to UAE

The headquarters of Daewoong Pharmaceutical South Korea's Daewoong Pharmaceutical announced on Monday that it exported its technology for clinical development and commercialization rights of its DWJ108U Depot injection (Leuprolide) product in the US to a UAE-based Zydus Worldwide DMCC.The contr

Daewoong Pharma's GER drug gets product OK from Mexico

Daewoong Pharma's GER drug gets product OK from Mexico

South Korea’s Daewoong Pharmaceutical on Wednesday said its gastroesophageal reflux (GER) disease drug Fexuclue (active ingredient fexuprazan hydrochloride) has received product approval from Mexico’s COFEPRIS, or the Federal Committee for Protection from Sanitary Risks.Mexico is t
(* comment hide *}